2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1857

A Novel Highly Selective 5-Hydroxytryptamine 2B (5-HT2B) Receptor Antagonist Ameliorating Fibrosis in Preclinical Models of Systemic Sclerosis
Abstract Number: 1858

Phenotypical and Functional Characteristics of in Vitro Expanded Adipose-Derived Mesenchymal Stem Cells from Patients with Systemic Sclerosis
Abstract Number: 1859

Fucosyltransferase-1 Mediated Fucosylation of TGF-βR1 Is Critical to TGF-β Signaling in Scleroderma and in Bleomycin-Induced Fibrosis
Abstract Number: 1860

Activating Transcription Factor 3 – a New Linkage Between Vasculopathy and Organ Fibrosis in Systemic Sclerosis
Abstract Number: 1861

Modelling the Interaction Between Disease Microenvironment and Mesenchymal Cells in Systemic Sclerosis
Abstract Number: 1862

Modelling Healthy and Scleroderma Fibrotic Skin in Vitro: Mechanical Stress Alters Macrophage Cytokine Expression and Triggers Signalling Via the Mechano-Sensing Transcription Factor Myocardin-Related Transcription Factor-a
Abstract Number: 1863

Non-Invasive Investigation of Perfusion, Microvascular Structure, Erythema, Oxidative Stress and Oxygenation in Healthy Controls and in Patients with Primary and Secondary Raynaud’s Phenomenon
Abstract Number: 1864

No Evidence of Association of ATP8B4 F436L missense Variant in a Large Systemic Sclerosis Cohort
Abstract Number: 1865

Urinary Cell Adhesion Molecules As Markers of Renal Involvement in Systemic Sclerosis
Abstract Number: 1866

Human and Experimental Tracheal Stenosis Is Characterized By a TGF-β-Dependent Fibrotic Component
Abstract Number: 1867

An Abnormal Nailfold Capillaroscopy Pattern Is Common in Patients with Connective Tissue Disease and Is Associated with Pulmonary and Oesophageal Involvement, Even in the Absence of Systemic Sclerosis
Abstract Number: 1868

Rates and Predictors of Physical Therapy and Occupational Therapy Utilization in Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study
Abstract Number: 1869

Mental Health Care in Systemic Sclerosis; Rates of Utilization and Associated Factors in the Scleroderma Patient-Centered Intervention Network Cohort
Abstract Number: 1870

First Pilot Study of an Implantable Loop Recorder (ILR) in Systemic Sclerosis Detects Significant Cardiac Arrhythmias with CMR Abnormalities
Abstract Number: 1871

Predicting Vascular Complications in Systemic Sclerosis: A Prospective Cohort Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].